Deal of the Day — limited-time pharmacy picks!
Ibrunat 140mg Tablet

Ibrunat 140mg Tablet

Prescription requiredRx Required

Salt Composition: Ibrutinib

Expiry Date: 01/2028

Special offer

Buy at $165.06

$165.06

Inclusive of all taxes

▼

30 capsule(s) in a bottle

About The Product

Chronic lymphocytic leukemia, lymphocytic lymphoma


Description

Ibrunat 140mg tablet is a prescription-based medicine used in the treatment of mantle cell lymphoma, blood cancer, and chronic lymphocytic leukemia. The medication's active ingredient is Ibrutinib, which belongs to the drug class of Bruton's tyrosine kinase (BTK) inhibitors.

It is a type of anticancer therapy that works by blocking the BTK enzyme, thereby preventing cancer cell growth and helping to slow down the disease progression. A doctor's prescription is required as the medicine is not recommended for an adult child under the age of 18.

Uses

  • Blood cancer (Chronic lymphocytic leukemia
  • Mantle-cell lymphoma

Side Effects

Ibrunat 140mg tablet causes certain side effects that are harmful to the body. Some of them are mild, and some are acute. If the symptoms persist or worsen, it is important to visit a healthcare professional immediately. Common ones include:

  • Muscle and bone pain
  • Rash and bruising
  • Mouth sores
  • Pneumonia
  • Fever, chills
  • Breathlessness
  • Constipation
  • Dizziness
  • Body pain
  • Swollen ankles and feet
  • Increased creatinine levels in the blood

  • Bleeding problems
  • Infections
  • Decrease in blood cell counts
  • Heart problems
  • High BP
  • Nausea
  • Vomiting
  • Diarrhea
  • Tiredness

How To Use

  • Ibrunat 140mg tablet should be taken at the same time everyday.
  • The medication is taken orally with or without food as directed by the healthcare professional.
  • Do not chew, crush or break the tablet just take it with a whole glass of water.
  • Never skip or overdose on the missed one without consultation with a doctor as this may cause side effects that could interfere with the effectiveness and safety of the treatment.
  • Always consult with the healthcare professional before using the medicine.

How It Works

The BTK enzyme plays an important role in B cell receptor signaling. In normal B cells, BTK function is helpful but in cancerous B cells, BTK activity becomes abnormal, causing cancer cells to grow and survive more than they should. Ibrunat 140mg tablet contains BTK inhibitors that block the enzyme and prevent the body from cancer growth and prevent the body from further growing cancer.

Safety Advice

Alcohol
Doctor’s avoid alcohol while taking Ibrunat 140mg tablet as it harms the effectiveness of the treatment and increase the risk of side effects.
Pregnancy
Pregnant women should avoid Ibrunat 140mg tablet a it harms the fetus and may cause complications during pregnancy.
Breast Feeding
Ibrunat 140mg tablet is unsafe during breastfeeding; reports suggest the drug may harm the baby.
Driving
Ibrunat 140mg tablet contains dizziness and sleepiness; do not drive while taking the medication. For more information visit the doctor Immedietly.
Kidney
Ibrunat 140mg tablet is not prescribed for kidney patients, as it may worsen kidney function or lead to complications, take a prescription from a healthcare provider.
Liver
Ibrunat 140mg tablet is unsafe for liver patients, as it can cause serious liver damage and worsen existing liver conditions, consult the doctor before use it.

FAQs

Ibrunat 140mg tablet should be taken with other medications, but the correct information should be suggested by the doctor only.

References

  • Cameron, F., & Sanford, M. (2014). Ibrutinib: first global approval. Drugs, 74(2), 263-271. https://pubmed.ncbi.nlm.nih.gov/24464309/
  • Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., ... & Kipps, T. J. (2015). Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine, 373(25), 2425-2437. https://pubmed.ncbi.nlm.nih.gov/26639149/
  • Charalambous, A., Schwarzbich, M. A., & Witzens-Harig, M. (2018). Ibrutinib. In Small Molecules in Hematology (pp. 133-168). Cham: Springer International Publishing. https://pubmed.ncbi.nlm.nih.gov/30069629/
  • Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J., Danilov, A. V., & DeLoughery, T. G. (2017). Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies. Journal of thrombosis and haemostasis, 15(5), 835-847. https://pubmed.ncbi.nlm.nih.gov/28182323/
  • Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., ... & Tallman, M. (2019). Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. New England Journal of Medicine, 381(5), 432-443. https://pubmed.ncbi.nlm.nih.gov/31365801/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026